Chemiluminescence Immunoassay Market by Product (Instruments, Consumables), Technology (CLEIA, ECLI, Microparticle CLIA), Sample Type (Blood, Saliva), Application (Oncology, Cardiology), End User (Hospital, Clinical Laboratory) - Global Forecast to 2031

The chemiluminescence immunoassay market is projected to reach USD 16.39 billion by 2031 from USD 11.58 billion in 2026, at a CAGR of 7.2% from 2026 to 2031.

The global market for CLIA testing systems is growing as people need accurate diagnostic tests to identify chronic and infectious diseases, including cancer, cardiovascular disorders, thyroid diseases, and viral infections. The increasing need for early disease detection, together with preventive healthcare approaches, leads to greater use of CLIA testing because it provides excellent sensitivity and a wide testing range and can identify trace amounts of biomarkers. The development of automated high-throughput testing systems, together with more stable testing materials and the ability to conduct multiple tests simultaneously, has improved laboratory productivity while decreasing testing duration. The market growth benefits from improved healthcare facilities, expanded testing laboratory systems, and increased medical expenditures that emerging markets are experiencing. The rising importance of biomarker testing for personalized medicine, drug development, and clinical research, together with strict blood screening regulations and health checkup awareness, boosts the need for CLIA systems in hospitals and reference laboratories throughout the world.

“Based on the product, the consumables segment is expected to grow at the highest CAGR in the CLIA market.”

The consumables segment of the CLIA market is growing because diagnostic testing requires laboratories to use reagents, calibrators, controls, and reaction vessels multiple times throughout their workday. Assay kits and reagent packs that hospitals and reference laboratories use daily see increased demand because infectious disease tests, oncology marker tests, cardiac biomarker tests, endocrine disorder tests, and therapeutic drug monitoring tests are being performed more frequently. Consumables require continuous replacement, which generates ongoing revenue while driving market growth, in contrast to analyzers. The adoption of new technologies that enhance reagent stability and ready-to-use product development and extended shelf-life capabilities leads to higher operational efficiency and lower material waste in laboratory workflows. The expansion of automated high-throughput CLIA systems, together with increased preventive health screening programs, higher blood safety testing, and expanded test menu options, is driving up consumables consumption, which makes this segment a key driver of overall CLIA market expansion.

“Based on application, the oncology segment is expected to grow with the highest CAGR in the CLIA market.”

The CLIA market in oncology applications shows growth because cancer cases are increasing worldwide, and there is greater demand for early diagnosis, prognosis evaluation, and treatment assessment. CLIA technology enables the detection of tumor markers through highly sensitive and specific methods, which include PSA, CA-125, CEA, AFP, and HER2 as diagnostic tools for initial patient evaluation and progress assessment of their medical condition. The rise in biomarker-based testing and precision oncology practices has created a need for dependable immunoassays, which assist in determining targeted therapies and individualized treatment options. The clinical use of CLIA tests has grown because these tests now help doctors monitor patient treatment response, identify cancer recurrences, and assess patients who have a high risk of developing cancer. The introduction of better assay systems, which enhance test sensitivity through automated processes and multiplex testing features, will continue to drive businesses toward adopting CLIA systems in their cancer diagnostic processes.

“Based on the end user, the hospitals segment is expected to grow by the highest CAGR in the CLIA market.”

Hospitals need to conduct accurate tests for various medical conditions, including cardiac markers, sepsis indicators, cancer biomarkers, hormone levels, and infectious pathogens. The CLIA systems enable emergency departments, intensive care units, and inpatient services to start treatment without delay through their advanced sensitivity, extensive testing capabilities, and quick result delivery. The move to centralized diagnostic systems, together with automated diagnostic machines, helps hospitals to cut down on manual tasks while achieving better operational results through standardized processes. The worldwide implementation of CLIA analyzers and assays in hospital systems accelerates because hospitals expand their facilities, and preventive health screening programs become more popular, accreditation and quality standards increase, and hospitals need complete laboratory information systems.

“APAC is estimated to register the highest CAGR during the forecast period.”

The CLIA market in the Asia Pacific region is growing due to three factors: expanding healthcare, rising healthcare spending, and improved distribution of diagnostic services in countries such as China, India, and Southeast Asia. The rising need for precise early diagnostic tests results from the increasing incidence of chronic illnesses, infectious diseases, and conditions linked to lifestyle choices. The government modernization projects, which include hospital upgrades, laboratory automation, and the development of a national screening program, accelerate the implementation of high-throughput CLIA systems. The demand for advanced immunoassay technologies grows due to three factors, which include increasing public knowledge about preventive healthcare, expanding private diagnostic laboratory networks, and rising medical tourism. The regional growth of the market benefits from three factors, which include a large patient base, better insurance access, and the market's shift toward automated laboratory systems that manage high testing loads. The widespread implementation of CLIA platforms throughout APAC results from two factors, which include ongoing international diagnostic company expansion and the rise of affordable domestic manufacturers.

Key players in the CLIA market

The key players in the market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), DiaSorin S.p.A. (Italy), QuidelOrtho Corporation (US), Sysmex Corporation (Japan), Shenzhen New Industry Biomedical Engineering Co., Ltd. (SNIBE Diagnostics) (China), Tosoh Corporation (Japan), Werfen (Spain), Bio-Rad Laboratories, Inc. (US), Shenzhen Mindray Biomedical Electronics Co., Ltd. (China), Fujirebio (Japan), HUMAN Gesellschaft für Biochemica und Diagnostica mbH. (Germany), EUROIMMUN Medizinische Labordiagnostika AG (Germany), Agappe Diagnostics Ltd (India), Zecen Biotech Co., Ltd (China), Maccura Biotechnology Co., Ltd (China), Autobio Diagnostics Co., Ltd. (China), Artron Laboratories Inc.(Canada), Abnova Corporation (Taiwan), Beijing Hotgen Biotech Co., Ltd (China), and Shanghai Kehua Bio-Engineering Co., Ltd. (China).

Research Coverage:

The report analyzes the CLIA market and aims at estimating the market size and future growth potential of this market based on various segments such as product type, sample type, technology, application, and end user. The report also includes a product portfolio matrix of various CLIA available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall CLIA market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights into the following pointers:

• Analysis of key drivers (increasing incidences of chronic and infectious diseases globally, advancements in improving CLIA technologies in recent years, rapid increase in geriatric population globally, growth of biotechnology and biopharmaceutical industries), restraints (high cost associated with placement and maintenance of CLIA, product recalls and failures), challenges (shortage of skilled professionals, risks associated with CLIAs), and opportunities (growth potential in emerging economies)
• Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global CLIA market
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the global CLIA market
• Market Development: Comprehensive information on the lucrative emerging markets by product type, technology, sample type, application, and end user
• Market Diversification: Exhaustive information about new products and services or product and service enhancements, growing geographies, recent developments, and investments in the global CLIA market
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products and services, and capacities of the major competitors in the global CLIA market

Show more